AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Indivior Pharmaceuticals Inc
Video analysis: INDV
All videosNo video analysis for this stock yet. Request one from our team.
News: INDV
HighTower Advisors LLC Makes New $3.41 Million Investment in Indivior PLC $INDV
HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 83,088 shares of the company's stock, valued at approximately $3,409,000. HighTower Advisors LLC owned about 0.07% of Indivior at the
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. U
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages Indivior shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersa.
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) PR Newsw
Similar companies
-
Lantheus Holdings, Inc.
LNTH
·
NASDAQ
Compare
-
Supernus Pharmaceuticals, Inc.
SUPN
·
NASDAQ
Compare
-
ACADIA Pharmaceuticals Inc.
ACAD
·
NASDAQ
Compare
-
Amneal Pharmaceuticals, Inc.
AMRX
·
NASDAQ
Compare
-
Hinge Health, Inc.
HNGE
·
New York Stock Exchange
Compare
-
ADMA Biologics, Inc.
ADMA
·
NASDAQ
Compare